Home Cannabis Why doctors don't trust cannabis as a medicine

Why doctors don't trust cannabis as a medicine

by Ties Inc.

2020-06-12- Why doctors don't trust cannabis as a medicine

People have been using cannabis for medicinal purposes for thousands of years. This is evident from ancient Egyptian medical texts, such as the Ebers Papyrus (1550 BC). Despite this rich history and enormous potential, medical cannabis is the exception rather than the rule.

Descriptions of medicinal cannabis have also been found in ancient Chinese, Greek, Indian and Islamic texts. However, it wasn't until the 19th century that cannabis made its way into Western medicine, where it was recognized as an effective treatment for muscle spasms, stomach cramps and chronic pain.

Medicinal marijuana

Before the United States' cannabis ban went into effect in the XNUMXs, hundreds, if not thousands, of proprietary drugs were produced that contained cannabis in their formulations. The exact number is difficult to determine, as manufacturers were not required to disclose the ingredients used in their medicines at this time. Even after marijuana was banned, Americans continued to use it illegally for medicinal purposes, willing to risk the legal ramifications. That already indicates the potential of cannabis as a medicine.

Even when the federal government banned the use of cannabis, it simultaneously recognized its medicinal potential. The US Food and Drug Administration (FDA) approved the drug dronabino, a synthetic form of tetrahydrocannabinol (THC), in 1970. The final turnaround followed in 1996: California became the first state to legalize cannabis for medicinal use.

33 States

From then on, there has been a drastic turnaround and 33 states in the U.S. have legalized the medical use of cannabis or its derivatives. Despite this rich history and enormous potential, many doctors worldwide do not trust or are permitted to prescribe cannabis as a drug by law. This is largely due to the relatively small number of clinical studies completed to date. The answer is largely due to the relatively small number of clinical studies completed to date, focusing on the medical efficacy of cannabis and its derivatives.

Evidence-based medicine

Western healthcare is strongly rooted in evidence-based medicine, with the premise that medical decisions and recommendations should be based on scientific evidence, not just the practitioner's beliefs. Without a large body of clinical research documenting the efficacy of cannabis, it is difficult for doctors to prescribe it to their patients. GW Pharmaceuticals, Tetra Bio-pharma and others are currently conducting clinical research on the development and production of FDA-approved cannabinoid-based therapeutics. There are more and more patients who want to try cannabis as a medicine. With that, the need for medical professionals who can make recommendations on its use is growing. A survey of cancer patients in Washington state found that 74 percent wanted information about cannabis use from their cancer care team. Only 15 percent actually received information from their doctor or nurse.

General confusion

The lack of clinical research on the medicinal value of cannabis can be attributed to a combination of factors, including:

  • A ban on the medical use of marijuana
  • Skepticism about Eastern medical practices among Western medical professionals
  • Confusion of patients about the possibilities and the lack of information

However, things are starting to change as federal restrictions on growing and processing hemp (marijuana's non-psychoactive cousin) are released. Traditional Eastern medical practices are widely accepted by medical professionals in the West and the public can learn more about cannabis products like cannabidiol.

Clinical research

As a result, clinical research on cannabis and cannabinoids has grown enormously over the past decade, and the results are still very promising - especially in palliative care and oncology. One of the world leaders in cannabis-specific clinical research is the Israeli company Tikun Olam. Tikun Olam has treated more than 10.000 patients with cannabinoid-based therapies, providing the world's largest database of patient data relevant to cannabinoid treatments. In 2018, researchers at Soroka Medical Center, the second largest hospital in Israel, analyzed Tikun Olam data from cancer patients treated with medical cannabis between 2015 and 2017. They found that after six months of treatment, 36 percent stopped using opioids and 95,9 percent lowered their opioid dose. In addition, XNUMX percent of patients reported an overall improvement in their condition.

Against cancer

Other recent studies have shown that CBD can reduce tumor size, the potential for invasion and metastasis, and the development of blood cancers. There is also some evidence that CBD in combination with traditional chemotherapy may be even more effective than CBD alone.
Also contributing to the growing number of cannabinoid clinical trials is Jay Pharma, a biopharmaceutical and wellness company developing innovative, evidence-based cannabinoid products and combination therapies to address unmet needs in cancer care. plans to initiate a phase I / II clinical trial of combined cannabinoid therapies aimed at improving outcomes and survival for patients diagnosed with glioblastoma multiforme (GM).

One of the most common and aggressive malignant primary brain tumors. At the same time, Jay Pharma is developing a CBD-based natural moisturizing ointment that aims to provide cancer patients with relief from radiodermatitis. A pilot study is planned for breast cancer patients who receive radiation therapy at a leading cancer center.

These and future clinical studies will contribute to a growing body of empirical evidence of medical cannabis and derivatives. We hope this will lead to more confidence and more education and guidance in the field of cannabinoid therapies. So that both doctors and patients can make better use of cannabis as a medicine.

Read more oncozine.com (Source, EN)

Related Articles